IL148405A0 - Antibody dye cojugates for binding to target structures of angiogenesis in order to intraoperatively depict tumor peripheries - Google Patents

Antibody dye cojugates for binding to target structures of angiogenesis in order to intraoperatively depict tumor peripheries

Info

Publication number
IL148405A0
IL148405A0 IL14840500A IL14840500A IL148405A0 IL 148405 A0 IL148405 A0 IL 148405A0 IL 14840500 A IL14840500 A IL 14840500A IL 14840500 A IL14840500 A IL 14840500A IL 148405 A0 IL148405 A0 IL 148405A0
Authority
IL
Israel
Prior art keywords
cojugates
intraoperatively
angiogenesis
binding
order
Prior art date
Application number
IL14840500A
Other languages
English (en)
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7924318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL148405(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of IL148405A0 publication Critical patent/IL148405A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0039—Coumarin dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL14840500A 1999-09-24 2000-08-19 Antibody dye cojugates for binding to target structures of angiogenesis in order to intraoperatively depict tumor peripheries IL148405A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19947559A DE19947559A1 (de) 1999-09-24 1999-09-24 Antikörper-Farbstoffkonjugate gegen Zielstrukturen der Angiogenese zur intraoperativen Tumorranddarstellung
PCT/EP2000/008121 WO2001023005A1 (de) 1999-09-24 2000-08-19 Antikörper-farbstoffkonjugate gegen zielstrukturen der angiogenese zur intraoperativen tumorranddarstellung

Publications (1)

Publication Number Publication Date
IL148405A0 true IL148405A0 (en) 2002-09-12

Family

ID=7924318

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14840500A IL148405A0 (en) 1999-09-24 2000-08-19 Antibody dye cojugates for binding to target structures of angiogenesis in order to intraoperatively depict tumor peripheries
IL148405A IL148405A (en) 1999-09-24 2002-02-27 Apply dye-antibody to link to target structures of blood vessel formation in order to mark while linking the tumor boundaries

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL148405A IL148405A (en) 1999-09-24 2002-02-27 Apply dye-antibody to link to target structures of blood vessel formation in order to mark while linking the tumor boundaries

Country Status (23)

Country Link
EP (2) EP1532988A3 (no)
JP (1) JP2003510294A (no)
KR (2) KR100832937B1 (no)
CN (1) CN1269530C (no)
AU (1) AU779026B2 (no)
BG (1) BG65682B1 (no)
BR (1) BR0014192A (no)
CA (1) CA2385593A1 (no)
CZ (1) CZ2002991A3 (no)
DE (1) DE19947559A1 (no)
EE (1) EE05176B1 (no)
HK (1) HK1050491A1 (no)
HU (1) HUP0202625A2 (no)
IL (2) IL148405A0 (no)
MX (1) MXPA02002639A (no)
NO (1) NO20021441L (no)
NZ (1) NZ517944A (no)
RO (1) RO121598B1 (no)
RU (1) RU2002109237A (no)
SK (1) SK3972002A3 (no)
WO (1) WO2001023005A1 (no)
YU (1) YU20702A (no)
ZA (1) ZA200203225B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1259548A1 (en) 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
US6440389B1 (en) * 2000-07-19 2002-08-27 The General Hospital Corporation Fluorescent agents for real-time measurement of organ function
AT413487B (de) 2002-08-12 2006-03-15 Igeneon Krebs Immuntherapie Verwendung von antikörpern gegen ein tumor-assoziiertes antigen
NO20034351D0 (no) * 2003-09-29 2003-09-29 Amersham Health As Optisk avbilding av endometrose
EP1816475A1 (en) * 2004-07-22 2007-08-08 Bayer Schering Pharma Aktiengesellschaft Use of cyanine dyes for the diagnosis of disease associated with angiogenesis
EP1679082A1 (en) * 2005-01-07 2006-07-12 Schering AG Use of cyanine dyes for the diagnosis of proliferative diseases
AU2010239272B2 (en) * 2009-04-21 2015-09-17 The University Of Utah Research Foundation Light-emitting dye for intraoperative imaging or sentinel lymph node biopsy
WO2018026965A1 (en) * 2016-08-02 2018-02-08 Isi Life Sciences, Inc. Compositions and methods for detecting cancer cells in a tissue sample

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341223A (en) * 1981-02-04 1982-07-27 Lutz Lauralee A Fluoresceable composition and method of determining fluid flow
CA2194369C (en) * 1994-07-11 2004-08-31 Philip E. Thorpe Methods and compositions for the specific coagulation of vasculature
TWI259837B (en) * 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis

Also Published As

Publication number Publication date
NO20021441D0 (no) 2002-03-22
RU2002109237A (ru) 2003-11-27
CN1376074A (zh) 2002-10-23
AU779026B2 (en) 2005-01-06
HUP0202625A2 (en) 2002-12-28
SK3972002A3 (en) 2002-09-10
KR20070087232A (ko) 2007-08-27
ZA200203225B (en) 2003-07-23
CN1269530C (zh) 2006-08-16
EP1532988A3 (de) 2008-09-17
EE200200152A (et) 2003-04-15
NZ517944A (en) 2004-06-25
DE19947559A1 (de) 2001-04-19
BG106528A (bg) 2002-12-29
KR20020039349A (ko) 2002-05-25
PL354027A1 (en) 2003-12-15
EP1532988A2 (de) 2005-05-25
HK1050491A1 (en) 2003-06-27
NO20021441L (no) 2002-05-15
RO121598B1 (ro) 2007-12-28
AU6702600A (en) 2001-04-30
CZ2002991A3 (cs) 2002-06-12
BG65682B1 (bg) 2009-06-30
BR0014192A (pt) 2002-05-21
CA2385593A1 (en) 2001-04-05
MXPA02002639A (es) 2002-07-30
EE05176B1 (et) 2009-06-15
JP2003510294A (ja) 2003-03-18
YU20702A (sh) 2005-06-10
EP1214099A1 (de) 2002-06-19
KR100832937B1 (ko) 2008-05-27
WO2001023005A1 (de) 2001-04-05
IL148405A (en) 2009-06-15

Similar Documents

Publication Publication Date Title
EP1187633A4 (en) USE OF ANTI-VEGF ANTIBODY FOR INCREASING IRRADIATION IN CANCER THERAPY
AU3041100A (en) Binding of antibody fragments to solid supports
NO20016114L (no) Preparater og fremgangsmåter for å öke kolesterolutströmming og heve HDL ved anvendelse av ATP-bindingskassett-transportörprotein ABC1
AP2000001983A0 (en) Antibodies to cd23 derivatives thereof and their therapeutic uses
IS2468B (is) Aðferðir og milliefni til framleiðslu á efnasamböndum gegn krabbameini
AU2605501A (en) Inducing cellular immune responses to prostate cancer antigens using peptide andnucleic acid compositions
EP1224274A4 (en) TUMORNESCROSE FACTOR RELATED RECEPTOR, TR6
HK1038512A1 (en) Methods of inducing cancer cell death and tumor regression
NO20011674D0 (no) Stropplös tålås-binding for snowboards
IL148405A0 (en) Antibody dye cojugates for binding to target structures of angiogenesis in order to intraoperatively depict tumor peripheries
IS5502A (is) Samtengd efnasambönd nytsamleg við meðhöndlun á krabbameini í blöðruhálskirtli
NO20023971D0 (no) Hormonterapi ved brystcancer
DE60031784D1 (de) Verbesserte hochtemperatursupraleiter-beschichtete elemente
EP1208232A4 (en) PROSTATE CANCER MARKERS
EP1191940A4 (en) TUMORNESCROSE FACTOR RECEPTOR 5
EG22346A (en) Process for the preparation of conjugates useful in the treatment of prostate cancer
NO20013607D0 (no) Skibinding for telemarkski
EP1210370A4 (en) TUMOR NECROSIS FACTOR TR16 HUMAN RECEPTOR
GB9916874D0 (en) Improvements to indoor winter sports
NZ523207A (en) Antibodies that bind to tumor gene sequences
TW410784U (en) Improved structure of hydraulic brake
GB2349322B (en) Improvements relating to heating elements
GB9921046D0 (en) Therapeutic antibody composition & use
NZ523209A (en) Antibodies that bind to tumor gene sequences
NO990561L (no) FremgangsmÕte for fremstilling av ski